Consensus Aprea Therapeutics, Inc.

Stocks

APRE

US03836J2015

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 31/10/2026 +04			5-day change	1st Jan Change
0.4846 ^USD	-1.82%		-6.39%	-43.19%

10-14	Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target	MT
08-28	Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs	CI

Evolution of the Average Target: Aprea Therapeutics, Inc.

Evolution of the Target Price: Aprea Therapeutics, Inc.

Changes in Analyst Recommendations: Aprea Therapeutics, Inc.

ccdebfb8339209bdb5370e08d0a.Oh6iq0pjMNgLB4gQKiS4R3PNq63x8ffui0Ty7A8i7NM.Y3300w4nQ6BjMeVnE2yOADiExvq9x5GhzgnKtkx6uL5RKOz6Ay53kVIz6w~e96d389631967bd66af20d62575bab3c

Analysts' recommendations: Aprea Therapeutics, Inc.

10-14	Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target	MT
08-12	Wedbush Adjusts Aprea Therapeutics Price Target to $3 From $6, Maintains Outperform Rating	MT
05-14	Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating	MT
05-07	Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target	MT
02-10	Wedbush Cuts Price Target on Aprea Therapeutics to $7 From $11, Keeps Outperform Rating	MT
24/10/25	Aprea sees early activity in APR-1051 Wee1 trial	RE
27/03/24	Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating	MT
10/04/23	Wedbush Raises Aprea Therapeutics' PT to $9 From $3, Says Keeps Outperform Rating; Continues to View Shares as 'Intriguingly Valued'	MT
10/03/23	Maxim Initiates Aprea Therapeutics at Buy Rating With $16 Price Target	MT
10/10/22	HC Wainwright Assumes Aprea Therapeutics at Buy with $3 Price Target	MT
08/07/22	Wedbush Initiates Aprea Therapeutics With Outperform Rating, $3 Price Target	MT
01/07/22	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	MT
25/05/22	Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold Rating	MT
16/03/22	HC Wainwright Adjusts Aprea Therapeutics' Price Target to $2 From $4, Maintains Neutral Rating	MT
16/03/22	RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Rating, Speculative Risk Qualifier	MT
20/08/21	Aprea Therapeutics : JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral	MT
16/08/21	Aprea Therapeutics : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6, Keeps Neutral Rating	MT
16/08/21	Aprea Therapeutics : Berenberg Bank Downgrades Aprea Therapeutics to Hold From Buy Following Clinical Hold on Myeloid/Lymphoid Program, Adjusts PT to $4 From $10	MT
13/08/21	Aprea Therapeutics : RBC Cuts Price Target on Aprea Therapeutics to $5 From $6 Amid FDA Hold on Lymphoid Malignancy Trial; Sector Perform-Speculative Risk Rating Kept	MT
13/08/21	Aprea Therapeutics : Morgan Stanley Lowers Aprea Therapeutics to Underweight From Equal-Weight, Price Target to $3 From $5	MT
09/08/21	Aprea Therapeutics : RBC Reduces Price Target on Aprea Therapeutics to $6 From $7, Maintains Sector Perform, Speculative Risk	MT
07/05/21	Aprea Therapeutics : RBC Cuts Price Target on Aprea Therapeutics to $7 From $8, Maintains Sector Perform, Speculative Risk	MT
17/03/21	Aprea Therapeutics : RBC Cuts Price Target on Aprea Therapeutics to $8 From $10, Maintains Sector Perform-Speculative Risk Rating	MT
29/12/20	Aprea Therapeutics : Morgan Stanley Adjusts Aprea Therapeutics' Price Target to $6 From $34, Keeps Equal-Weight Rating	MT
29/12/20	Aprea Therapeutics : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $6 From $30, Maintains Neutral Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	APREA THERAPEUTICS, INC.					+580.97%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.88%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+84.13%
	Weighted average by Cap.					+27.09%